Skip to main content

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioMarin Pharmaceutical Inc.

By: Newsfile

Wilmington, Delaware--(Newsfile Corp. - February 3, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ: BMRN) on behalf of stockholders.

On October 25, 2021, a class action complaint was filed against BioMarin. The complaint alleges that, between January 13, 2020 and September 3, 2021, defendants made materially false and misleading statements regarding BioMarin's business, operations, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was not as safe as BioMarin led investors to believe; (ii) BMN 307's safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) thus, BioMarin overstated BMN 307's clinical and commercial prospects; and (iv) as a result, BioMarin's public statements were materially false and misleading.

To learn more about this investigation and your rights, visit:

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky Law, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.